Imugene Statistics
Total Valuation
Imugene has a market cap or net worth of 59.29 million. The enterprise value is 51.29 million.
| Market Cap | 59.29M |
| Enterprise Value | 51.29M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 321.52M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.90% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 8.52% |
| Owned by Institutions (%) | 5.57% |
| Float | 266.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.57 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 6.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.13 |
| EV / Sales | 16.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.94 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.88 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | -431.20 |
Financial Efficiency
Return on equity (ROE) is -84.54% and return on invested capital (ROIC) is -49.98%.
| Return on Equity (ROE) | -84.54% |
| Return on Assets (ROA) | -37.27% |
| Return on Invested Capital (ROIC) | -49.98% |
| Return on Capital Employed (ROCE) | -114.04% |
| Weighted Average Cost of Capital (WACC) | 16.66% |
| Revenue Per Employee | 576,518 |
| Profits Per Employee | -9.05M |
| Employee Count | 5 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.21% in the last 52 weeks. The beta is 2.59, so Imugene's price volatility has been higher than the market average.
| Beta (5Y) | 2.59 |
| 52-Week Price Change | -78.21% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 42.56 |
| Average Volume (20 Days) | 15,622 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imugene had revenue of 2.88 million and -45.25 million in losses. Loss per share was -0.21.
| Revenue | 2.88M |
| Gross Profit | 2.88M |
| Operating Income | -45.93M |
| Pretax Income | -45.25M |
| Net Income | -45.25M |
| EBITDA | -44.20M |
| EBIT | -45.93M |
| Loss Per Share | -0.21 |
Balance Sheet
The company has 14.38 million in cash and 6.98 million in debt, with a net cash position of 7.40 million.
| Cash & Cash Equivalents | 14.38M |
| Total Debt | 6.98M |
| Net Cash | 7.40M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 29.52M |
| Book Value Per Share | 0.13 |
| Working Capital | 12.85M |
Cash Flow
In the last 12 months, operating cash flow was -49.54 million and capital expenditures -4.95 million, giving a free cash flow of -54.49 million.
| Operating Cash Flow | -49.54M |
| Capital Expenditures | -4.95M |
| Free Cash Flow | -54.49M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,593.52% |
| Pretax Margin | -1,569.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Imugene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.90% |
| Shareholder Yield | -4.90% |
| Earnings Yield | -76.32% |
| FCF Yield | -91.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 2, 2025. It was a reverse split with a ratio of 0.0294118.
| Last Split Date | Jul 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0294118 |
Scores
Imugene has an Altman Z-Score of -3.85 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.85 |
| Piotroski F-Score | 1 |